?Global HPV Vaccines

HPV Vaccines Comprehensive Study by Type (Gardasils, Gardasil 9, Cervarix), Age Group (Adolescent, Adults), Disease Indication (Cervical Cancer, Cancer, Vaginal Cancer, Vulvar Cancer, Oropharyngeal Cancer, Others) Players and Region - Global Market Outlook to 2029

HPV Vaccines Market by XX Submarkets | Forecast Years 2024-2029  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About HPV Vaccines
HPV vaccines are the type of vaccines, which protect against infection with human papillomaviruses. HPV is a group of more than two hundred related viruses, of which more than forty are spread through direct sexual contact. Among these, several HPV types cause genital warts, and about a dozen types can cause certain types of cancers such as cervical, anal, oropharyngeal, vulvar, penile, and vaginal. Furthermore, the FDA has approved three vaccines such as Gardasil, Gardasil 9, and Cervarix that prevents infection with disease-causing HPV types. As of 2017, Gardasil 9 is the only HPV vaccine available for use in the United States. Cervarix and Gardasil are still used in other countries.

AttributesDetails
Study Period2019-2029
Base Year2023
UnitValue (USD Million)


The global market is highly competitive and consists of a limited number of providers who compete with each other. The intense competition, changing consumer spending patterns, demographic trends, and frequent changes in consumer preferences pose significant opportunities for market growth. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global HPV Vaccines market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Merck & Co., Inc. (United States), GlaxoSmithKline plc. (United Kingdom), Sanofi S.A. (France), Pfizer Inc. (United States), Johnson & Johnson (United States), Inovio Pharmaceuticals Inc. (United States), Bayer AG (Germany), Nuron Biotech Inc. (United States), EyeGene Inc. (South Korea) and MedImmune (United States) are some of the key players that are part of study coverage.

Segmentation Overview
AMA Research has segmented the market of Global HPV Vaccines market by Type (Gardasils, Gardasil 9 and Cervarix) and Region.



On the basis of geography, the market of HPV Vaccines has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Age Group, the sub-segment i.e. Adolescent will boost the HPV Vaccines market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Disease Indication, the sub-segment i.e. Cervical Cancer will boost the HPV Vaccines market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Growth Drivers:
Increasing Prevalence of Cancer, Growing Government Initiatives for Increasing Awareness and Funding To the Immunization Programs

Challenges:
Many people, especially adolescents and their parents, are unaware of HPV and the benefits of vaccination.

Restraints:
High Cost of Vaccine Manufacturing

Opportunities:
Research and Development Stimulate the Innovation of Novel Vaccines and The Emerging Demand from Developing Countries

Market Leaders and their expansionary development strategies
In March 2023, CAPED and Roche Diagnostics signed a Memorandum of Understanding (MoU) with the Cancer Awareness Prevention and Early Detection Trust (CAPED), a non-profit organization that promotes cancer awareness, prevention, and early detection. The partnership aimed to launch a Cervical Cancer screening program in India. Source: https://www.mordorintelligence.com/industry-reports/human-papillomavirus-vaccine-market
In 3 April 2019, Inovio Pharmaceuticals, Inc. announced its novel therapy INO-3106 against the human papilloma virus type 6 (HPV 6) demonstrated clinical efficacy in a study of two patients with recurrent respiratory papillomatosis (RRP). RRP is an HPV-associated disease that can cause noncancerous tumor growths leading to life-threatening airway obstructions and occasionally progresses to cancer. RRP is primarily caused by two strains of HPV, HPV 6 and 11, which also predominantly cause genital warts. RRP may occur in adults (adult-onset RRP) as well as in children (juvenile-onset RRP) who are thought to have contracted the virus during childbirth.
World Health Organization (WHO): Recommends routine HPV vaccination for all girls aged 9-14 years, with catch-up vaccination for older girls and women up to 26 years.

Key Target Audience
HPV Vaccine Manufacturers, HPV Vaccine Importer/Exporter, HPV Vaccine Distributors, Research Institutes, Regulatory & Government Bodies, End Users and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Gardasils
  • Gardasil 9
  • Cervarix
By Age Group
  • Adolescent
  • Adults

By Disease Indication
  • Cervical Cancer
  • Cancer
  • Vaginal Cancer
  • Vulvar Cancer
  • Oropharyngeal Cancer
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Prevalence of Cancer
      • 3.2.2. Growing Government Initiatives for Increasing Awareness
      • 3.2.3. Funding To the Immunization Programs
    • 3.3. Market Challenges
      • 3.3.1. Many people, especially adolescents and their parents, are unaware of HPV and the benefits of vaccination.
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global HPV Vaccines, by Type, Age Group, Disease Indication and Region (value, volume and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global HPV Vaccines (Value)
      • 5.2.1. Global HPV Vaccines by: Type (Value)
        • 5.2.1.1. Gardasils
        • 5.2.1.2. Gardasil 9
        • 5.2.1.3. Cervarix
      • 5.2.2. Global HPV Vaccines by: Age Group (Value)
        • 5.2.2.1. Adolescent
        • 5.2.2.2. Adults
      • 5.2.3. Global HPV Vaccines by: Disease Indication (Value)
        • 5.2.3.1. Cervical Cancer
        • 5.2.3.2. Cancer
        • 5.2.3.3. Vaginal Cancer
        • 5.2.3.4. Vulvar Cancer
        • 5.2.3.5. Oropharyngeal Cancer
        • 5.2.3.6. Others
      • 5.2.4. Global HPV Vaccines Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global HPV Vaccines (Volume)
      • 5.3.1. Global HPV Vaccines by: Type (Volume)
        • 5.3.1.1. Gardasils
        • 5.3.1.2. Gardasil 9
        • 5.3.1.3. Cervarix
      • 5.3.2. Global HPV Vaccines by: Age Group (Volume)
        • 5.3.2.1. Adolescent
        • 5.3.2.2. Adults
      • 5.3.3. Global HPV Vaccines by: Disease Indication (Volume)
        • 5.3.3.1. Cervical Cancer
        • 5.3.3.2. Cancer
        • 5.3.3.3. Vaginal Cancer
        • 5.3.3.4. Vulvar Cancer
        • 5.3.3.5. Oropharyngeal Cancer
        • 5.3.3.6. Others
      • 5.3.4. Global HPV Vaccines Region
        • 5.3.4.1. South America
          • 5.3.4.1.1. Brazil
          • 5.3.4.1.2. Argentina
          • 5.3.4.1.3. Rest of South America
        • 5.3.4.2. Asia Pacific
          • 5.3.4.2.1. China
          • 5.3.4.2.2. Japan
          • 5.3.4.2.3. India
          • 5.3.4.2.4. South Korea
          • 5.3.4.2.5. Taiwan
          • 5.3.4.2.6. Australia
          • 5.3.4.2.7. Rest of Asia-Pacific
        • 5.3.4.3. Europe
          • 5.3.4.3.1. Germany
          • 5.3.4.3.2. France
          • 5.3.4.3.3. Italy
          • 5.3.4.3.4. United Kingdom
          • 5.3.4.3.5. Netherlands
          • 5.3.4.3.6. Rest of Europe
        • 5.3.4.4. MEA
          • 5.3.4.4.1. Middle East
          • 5.3.4.4.2. Africa
        • 5.3.4.5. North America
          • 5.3.4.5.1. United States
          • 5.3.4.5.2. Canada
          • 5.3.4.5.3. Mexico
    • 5.4. Global HPV Vaccines (Price)
      • 5.4.1. Global HPV Vaccines by: Type (Price)
  • 6. HPV Vaccines: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Merck & Co., Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. GlaxoSmithKline plc. (United Kingdom)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Sanofi S.A. (France)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Pfizer Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Johnson & Johnson (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Inovio Pharmaceuticals Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Bayer AG (Germany)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Nuron Biotech Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. EyeGene Inc. (South Korea)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. MedImmune (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global HPV Vaccines Sale, by Type, Age Group, Disease Indication and Region (value, volume and price ) (2024-2029)
    • 7.1. Introduction
    • 7.2. Global HPV Vaccines (Value)
      • 7.2.1. Global HPV Vaccines by: Type (Value)
        • 7.2.1.1. Gardasils
        • 7.2.1.2. Gardasil 9
        • 7.2.1.3. Cervarix
      • 7.2.2. Global HPV Vaccines by: Age Group (Value)
        • 7.2.2.1. Adolescent
        • 7.2.2.2. Adults
      • 7.2.3. Global HPV Vaccines by: Disease Indication (Value)
        • 7.2.3.1. Cervical Cancer
        • 7.2.3.2. Cancer
        • 7.2.3.3. Vaginal Cancer
        • 7.2.3.4. Vulvar Cancer
        • 7.2.3.5. Oropharyngeal Cancer
        • 7.2.3.6. Others
      • 7.2.4. Global HPV Vaccines Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global HPV Vaccines (Volume)
      • 7.3.1. Global HPV Vaccines by: Type (Volume)
        • 7.3.1.1. Gardasils
        • 7.3.1.2. Gardasil 9
        • 7.3.1.3. Cervarix
      • 7.3.2. Global HPV Vaccines by: Age Group (Volume)
        • 7.3.2.1. Adolescent
        • 7.3.2.2. Adults
      • 7.3.3. Global HPV Vaccines by: Disease Indication (Volume)
        • 7.3.3.1. Cervical Cancer
        • 7.3.3.2. Cancer
        • 7.3.3.3. Vaginal Cancer
        • 7.3.3.4. Vulvar Cancer
        • 7.3.3.5. Oropharyngeal Cancer
        • 7.3.3.6. Others
      • 7.3.4. Global HPV Vaccines Region
        • 7.3.4.1. South America
          • 7.3.4.1.1. Brazil
          • 7.3.4.1.2. Argentina
          • 7.3.4.1.3. Rest of South America
        • 7.3.4.2. Asia Pacific
          • 7.3.4.2.1. China
          • 7.3.4.2.2. Japan
          • 7.3.4.2.3. India
          • 7.3.4.2.4. South Korea
          • 7.3.4.2.5. Taiwan
          • 7.3.4.2.6. Australia
          • 7.3.4.2.7. Rest of Asia-Pacific
        • 7.3.4.3. Europe
          • 7.3.4.3.1. Germany
          • 7.3.4.3.2. France
          • 7.3.4.3.3. Italy
          • 7.3.4.3.4. United Kingdom
          • 7.3.4.3.5. Netherlands
          • 7.3.4.3.6. Rest of Europe
        • 7.3.4.4. MEA
          • 7.3.4.4.1. Middle East
          • 7.3.4.4.2. Africa
        • 7.3.4.5. North America
          • 7.3.4.5.1. United States
          • 7.3.4.5.2. Canada
          • 7.3.4.5.3. Mexico
    • 7.4. Global HPV Vaccines (Price)
      • 7.4.1. Global HPV Vaccines by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. HPV Vaccines: by Type(USD Million)
  • Table 2. HPV Vaccines Gardasils , by Region USD Million (2018-2023)
  • Table 3. HPV Vaccines Gardasil 9 , by Region USD Million (2018-2023)
  • Table 4. HPV Vaccines Cervarix , by Region USD Million (2018-2023)
  • Table 5. HPV Vaccines: by Age Group(USD Million)
  • Table 6. HPV Vaccines Adolescent , by Region USD Million (2018-2023)
  • Table 7. HPV Vaccines Adults , by Region USD Million (2018-2023)
  • Table 8. HPV Vaccines: by Disease Indication(USD Million)
  • Table 9. HPV Vaccines Cervical Cancer , by Region USD Million (2018-2023)
  • Table 10. HPV Vaccines Cancer , by Region USD Million (2018-2023)
  • Table 11. HPV Vaccines Vaginal Cancer , by Region USD Million (2018-2023)
  • Table 12. HPV Vaccines Vulvar Cancer , by Region USD Million (2018-2023)
  • Table 13. HPV Vaccines Oropharyngeal Cancer , by Region USD Million (2018-2023)
  • Table 14. HPV Vaccines Others , by Region USD Million (2018-2023)
  • Table 15. South America HPV Vaccines, by Country USD Million (2018-2023)
  • Table 16. South America HPV Vaccines, by Type USD Million (2018-2023)
  • Table 17. South America HPV Vaccines, by Age Group USD Million (2018-2023)
  • Table 18. South America HPV Vaccines, by Disease Indication USD Million (2018-2023)
  • Table 19. Brazil HPV Vaccines, by Type USD Million (2018-2023)
  • Table 20. Brazil HPV Vaccines, by Age Group USD Million (2018-2023)
  • Table 21. Brazil HPV Vaccines, by Disease Indication USD Million (2018-2023)
  • Table 22. Argentina HPV Vaccines, by Type USD Million (2018-2023)
  • Table 23. Argentina HPV Vaccines, by Age Group USD Million (2018-2023)
  • Table 24. Argentina HPV Vaccines, by Disease Indication USD Million (2018-2023)
  • Table 25. Rest of South America HPV Vaccines, by Type USD Million (2018-2023)
  • Table 26. Rest of South America HPV Vaccines, by Age Group USD Million (2018-2023)
  • Table 27. Rest of South America HPV Vaccines, by Disease Indication USD Million (2018-2023)
  • Table 28. Asia Pacific HPV Vaccines, by Country USD Million (2018-2023)
  • Table 29. Asia Pacific HPV Vaccines, by Type USD Million (2018-2023)
  • Table 30. Asia Pacific HPV Vaccines, by Age Group USD Million (2018-2023)
  • Table 31. Asia Pacific HPV Vaccines, by Disease Indication USD Million (2018-2023)
  • Table 32. China HPV Vaccines, by Type USD Million (2018-2023)
  • Table 33. China HPV Vaccines, by Age Group USD Million (2018-2023)
  • Table 34. China HPV Vaccines, by Disease Indication USD Million (2018-2023)
  • Table 35. Japan HPV Vaccines, by Type USD Million (2018-2023)
  • Table 36. Japan HPV Vaccines, by Age Group USD Million (2018-2023)
  • Table 37. Japan HPV Vaccines, by Disease Indication USD Million (2018-2023)
  • Table 38. India HPV Vaccines, by Type USD Million (2018-2023)
  • Table 39. India HPV Vaccines, by Age Group USD Million (2018-2023)
  • Table 40. India HPV Vaccines, by Disease Indication USD Million (2018-2023)
  • Table 41. South Korea HPV Vaccines, by Type USD Million (2018-2023)
  • Table 42. South Korea HPV Vaccines, by Age Group USD Million (2018-2023)
  • Table 43. South Korea HPV Vaccines, by Disease Indication USD Million (2018-2023)
  • Table 44. Taiwan HPV Vaccines, by Type USD Million (2018-2023)
  • Table 45. Taiwan HPV Vaccines, by Age Group USD Million (2018-2023)
  • Table 46. Taiwan HPV Vaccines, by Disease Indication USD Million (2018-2023)
  • Table 47. Australia HPV Vaccines, by Type USD Million (2018-2023)
  • Table 48. Australia HPV Vaccines, by Age Group USD Million (2018-2023)
  • Table 49. Australia HPV Vaccines, by Disease Indication USD Million (2018-2023)
  • Table 50. Rest of Asia-Pacific HPV Vaccines, by Type USD Million (2018-2023)
  • Table 51. Rest of Asia-Pacific HPV Vaccines, by Age Group USD Million (2018-2023)
  • Table 52. Rest of Asia-Pacific HPV Vaccines, by Disease Indication USD Million (2018-2023)
  • Table 53. Europe HPV Vaccines, by Country USD Million (2018-2023)
  • Table 54. Europe HPV Vaccines, by Type USD Million (2018-2023)
  • Table 55. Europe HPV Vaccines, by Age Group USD Million (2018-2023)
  • Table 56. Europe HPV Vaccines, by Disease Indication USD Million (2018-2023)
  • Table 57. Germany HPV Vaccines, by Type USD Million (2018-2023)
  • Table 58. Germany HPV Vaccines, by Age Group USD Million (2018-2023)
  • Table 59. Germany HPV Vaccines, by Disease Indication USD Million (2018-2023)
  • Table 60. France HPV Vaccines, by Type USD Million (2018-2023)
  • Table 61. France HPV Vaccines, by Age Group USD Million (2018-2023)
  • Table 62. France HPV Vaccines, by Disease Indication USD Million (2018-2023)
  • Table 63. Italy HPV Vaccines, by Type USD Million (2018-2023)
  • Table 64. Italy HPV Vaccines, by Age Group USD Million (2018-2023)
  • Table 65. Italy HPV Vaccines, by Disease Indication USD Million (2018-2023)
  • Table 66. United Kingdom HPV Vaccines, by Type USD Million (2018-2023)
  • Table 67. United Kingdom HPV Vaccines, by Age Group USD Million (2018-2023)
  • Table 68. United Kingdom HPV Vaccines, by Disease Indication USD Million (2018-2023)
  • Table 69. Netherlands HPV Vaccines, by Type USD Million (2018-2023)
  • Table 70. Netherlands HPV Vaccines, by Age Group USD Million (2018-2023)
  • Table 71. Netherlands HPV Vaccines, by Disease Indication USD Million (2018-2023)
  • Table 72. Rest of Europe HPV Vaccines, by Type USD Million (2018-2023)
  • Table 73. Rest of Europe HPV Vaccines, by Age Group USD Million (2018-2023)
  • Table 74. Rest of Europe HPV Vaccines, by Disease Indication USD Million (2018-2023)
  • Table 75. MEA HPV Vaccines, by Country USD Million (2018-2023)
  • Table 76. MEA HPV Vaccines, by Type USD Million (2018-2023)
  • Table 77. MEA HPV Vaccines, by Age Group USD Million (2018-2023)
  • Table 78. MEA HPV Vaccines, by Disease Indication USD Million (2018-2023)
  • Table 79. Middle East HPV Vaccines, by Type USD Million (2018-2023)
  • Table 80. Middle East HPV Vaccines, by Age Group USD Million (2018-2023)
  • Table 81. Middle East HPV Vaccines, by Disease Indication USD Million (2018-2023)
  • Table 82. Africa HPV Vaccines, by Type USD Million (2018-2023)
  • Table 83. Africa HPV Vaccines, by Age Group USD Million (2018-2023)
  • Table 84. Africa HPV Vaccines, by Disease Indication USD Million (2018-2023)
  • Table 85. North America HPV Vaccines, by Country USD Million (2018-2023)
  • Table 86. North America HPV Vaccines, by Type USD Million (2018-2023)
  • Table 87. North America HPV Vaccines, by Age Group USD Million (2018-2023)
  • Table 88. North America HPV Vaccines, by Disease Indication USD Million (2018-2023)
  • Table 89. United States HPV Vaccines, by Type USD Million (2018-2023)
  • Table 90. United States HPV Vaccines, by Age Group USD Million (2018-2023)
  • Table 91. United States HPV Vaccines, by Disease Indication USD Million (2018-2023)
  • Table 92. Canada HPV Vaccines, by Type USD Million (2018-2023)
  • Table 93. Canada HPV Vaccines, by Age Group USD Million (2018-2023)
  • Table 94. Canada HPV Vaccines, by Disease Indication USD Million (2018-2023)
  • Table 95. Mexico HPV Vaccines, by Type USD Million (2018-2023)
  • Table 96. Mexico HPV Vaccines, by Age Group USD Million (2018-2023)
  • Table 97. Mexico HPV Vaccines, by Disease Indication USD Million (2018-2023)
  • Table 98. HPV Vaccines Sales: by Type(K Liters)
  • Table 99. HPV Vaccines Sales Gardasils , by Region K Liters (2018-2023)
  • Table 100. HPV Vaccines Sales Gardasil 9 , by Region K Liters (2018-2023)
  • Table 101. HPV Vaccines Sales Cervarix , by Region K Liters (2018-2023)
  • Table 102. HPV Vaccines Sales: by Age Group(K Liters)
  • Table 103. HPV Vaccines Sales Adolescent , by Region K Liters (2018-2023)
  • Table 104. HPV Vaccines Sales Adults , by Region K Liters (2018-2023)
  • Table 105. HPV Vaccines Sales: by Disease Indication(K Liters)
  • Table 106. HPV Vaccines Sales Cervical Cancer , by Region K Liters (2018-2023)
  • Table 107. HPV Vaccines Sales Cancer , by Region K Liters (2018-2023)
  • Table 108. HPV Vaccines Sales Vaginal Cancer , by Region K Liters (2018-2023)
  • Table 109. HPV Vaccines Sales Vulvar Cancer , by Region K Liters (2018-2023)
  • Table 110. HPV Vaccines Sales Oropharyngeal Cancer , by Region K Liters (2018-2023)
  • Table 111. HPV Vaccines Sales Others , by Region K Liters (2018-2023)
  • Table 112. South America HPV Vaccines Sales, by Country K Liters (2018-2023)
  • Table 113. South America HPV Vaccines Sales, by Type K Liters (2018-2023)
  • Table 114. South America HPV Vaccines Sales, by Age Group K Liters (2018-2023)
  • Table 115. South America HPV Vaccines Sales, by Disease Indication K Liters (2018-2023)
  • Table 116. Brazil HPV Vaccines Sales, by Type K Liters (2018-2023)
  • Table 117. Brazil HPV Vaccines Sales, by Age Group K Liters (2018-2023)
  • Table 118. Brazil HPV Vaccines Sales, by Disease Indication K Liters (2018-2023)
  • Table 119. Argentina HPV Vaccines Sales, by Type K Liters (2018-2023)
  • Table 120. Argentina HPV Vaccines Sales, by Age Group K Liters (2018-2023)
  • Table 121. Argentina HPV Vaccines Sales, by Disease Indication K Liters (2018-2023)
  • Table 122. Rest of South America HPV Vaccines Sales, by Type K Liters (2018-2023)
  • Table 123. Rest of South America HPV Vaccines Sales, by Age Group K Liters (2018-2023)
  • Table 124. Rest of South America HPV Vaccines Sales, by Disease Indication K Liters (2018-2023)
  • Table 125. Asia Pacific HPV Vaccines Sales, by Country K Liters (2018-2023)
  • Table 126. Asia Pacific HPV Vaccines Sales, by Type K Liters (2018-2023)
  • Table 127. Asia Pacific HPV Vaccines Sales, by Age Group K Liters (2018-2023)
  • Table 128. Asia Pacific HPV Vaccines Sales, by Disease Indication K Liters (2018-2023)
  • Table 129. China HPV Vaccines Sales, by Type K Liters (2018-2023)
  • Table 130. China HPV Vaccines Sales, by Age Group K Liters (2018-2023)
  • Table 131. China HPV Vaccines Sales, by Disease Indication K Liters (2018-2023)
  • Table 132. Japan HPV Vaccines Sales, by Type K Liters (2018-2023)
  • Table 133. Japan HPV Vaccines Sales, by Age Group K Liters (2018-2023)
  • Table 134. Japan HPV Vaccines Sales, by Disease Indication K Liters (2018-2023)
  • Table 135. India HPV Vaccines Sales, by Type K Liters (2018-2023)
  • Table 136. India HPV Vaccines Sales, by Age Group K Liters (2018-2023)
  • Table 137. India HPV Vaccines Sales, by Disease Indication K Liters (2018-2023)
  • Table 138. South Korea HPV Vaccines Sales, by Type K Liters (2018-2023)
  • Table 139. South Korea HPV Vaccines Sales, by Age Group K Liters (2018-2023)
  • Table 140. South Korea HPV Vaccines Sales, by Disease Indication K Liters (2018-2023)
  • Table 141. Taiwan HPV Vaccines Sales, by Type K Liters (2018-2023)
  • Table 142. Taiwan HPV Vaccines Sales, by Age Group K Liters (2018-2023)
  • Table 143. Taiwan HPV Vaccines Sales, by Disease Indication K Liters (2018-2023)
  • Table 144. Australia HPV Vaccines Sales, by Type K Liters (2018-2023)
  • Table 145. Australia HPV Vaccines Sales, by Age Group K Liters (2018-2023)
  • Table 146. Australia HPV Vaccines Sales, by Disease Indication K Liters (2018-2023)
  • Table 147. Rest of Asia-Pacific HPV Vaccines Sales, by Type K Liters (2018-2023)
  • Table 148. Rest of Asia-Pacific HPV Vaccines Sales, by Age Group K Liters (2018-2023)
  • Table 149. Rest of Asia-Pacific HPV Vaccines Sales, by Disease Indication K Liters (2018-2023)
  • Table 150. Europe HPV Vaccines Sales, by Country K Liters (2018-2023)
  • Table 151. Europe HPV Vaccines Sales, by Type K Liters (2018-2023)
  • Table 152. Europe HPV Vaccines Sales, by Age Group K Liters (2018-2023)
  • Table 153. Europe HPV Vaccines Sales, by Disease Indication K Liters (2018-2023)
  • Table 154. Germany HPV Vaccines Sales, by Type K Liters (2018-2023)
  • Table 155. Germany HPV Vaccines Sales, by Age Group K Liters (2018-2023)
  • Table 156. Germany HPV Vaccines Sales, by Disease Indication K Liters (2018-2023)
  • Table 157. France HPV Vaccines Sales, by Type K Liters (2018-2023)
  • Table 158. France HPV Vaccines Sales, by Age Group K Liters (2018-2023)
  • Table 159. France HPV Vaccines Sales, by Disease Indication K Liters (2018-2023)
  • Table 160. Italy HPV Vaccines Sales, by Type K Liters (2018-2023)
  • Table 161. Italy HPV Vaccines Sales, by Age Group K Liters (2018-2023)
  • Table 162. Italy HPV Vaccines Sales, by Disease Indication K Liters (2018-2023)
  • Table 163. United Kingdom HPV Vaccines Sales, by Type K Liters (2018-2023)
  • Table 164. United Kingdom HPV Vaccines Sales, by Age Group K Liters (2018-2023)
  • Table 165. United Kingdom HPV Vaccines Sales, by Disease Indication K Liters (2018-2023)
  • Table 166. Netherlands HPV Vaccines Sales, by Type K Liters (2018-2023)
  • Table 167. Netherlands HPV Vaccines Sales, by Age Group K Liters (2018-2023)
  • Table 168. Netherlands HPV Vaccines Sales, by Disease Indication K Liters (2018-2023)
  • Table 169. Rest of Europe HPV Vaccines Sales, by Type K Liters (2018-2023)
  • Table 170. Rest of Europe HPV Vaccines Sales, by Age Group K Liters (2018-2023)
  • Table 171. Rest of Europe HPV Vaccines Sales, by Disease Indication K Liters (2018-2023)
  • Table 172. MEA HPV Vaccines Sales, by Country K Liters (2018-2023)
  • Table 173. MEA HPV Vaccines Sales, by Type K Liters (2018-2023)
  • Table 174. MEA HPV Vaccines Sales, by Age Group K Liters (2018-2023)
  • Table 175. MEA HPV Vaccines Sales, by Disease Indication K Liters (2018-2023)
  • Table 176. Middle East HPV Vaccines Sales, by Type K Liters (2018-2023)
  • Table 177. Middle East HPV Vaccines Sales, by Age Group K Liters (2018-2023)
  • Table 178. Middle East HPV Vaccines Sales, by Disease Indication K Liters (2018-2023)
  • Table 179. Africa HPV Vaccines Sales, by Type K Liters (2018-2023)
  • Table 180. Africa HPV Vaccines Sales, by Age Group K Liters (2018-2023)
  • Table 181. Africa HPV Vaccines Sales, by Disease Indication K Liters (2018-2023)
  • Table 182. North America HPV Vaccines Sales, by Country K Liters (2018-2023)
  • Table 183. North America HPV Vaccines Sales, by Type K Liters (2018-2023)
  • Table 184. North America HPV Vaccines Sales, by Age Group K Liters (2018-2023)
  • Table 185. North America HPV Vaccines Sales, by Disease Indication K Liters (2018-2023)
  • Table 186. United States HPV Vaccines Sales, by Type K Liters (2018-2023)
  • Table 187. United States HPV Vaccines Sales, by Age Group K Liters (2018-2023)
  • Table 188. United States HPV Vaccines Sales, by Disease Indication K Liters (2018-2023)
  • Table 189. Canada HPV Vaccines Sales, by Type K Liters (2018-2023)
  • Table 190. Canada HPV Vaccines Sales, by Age Group K Liters (2018-2023)
  • Table 191. Canada HPV Vaccines Sales, by Disease Indication K Liters (2018-2023)
  • Table 192. Mexico HPV Vaccines Sales, by Type K Liters (2018-2023)
  • Table 193. Mexico HPV Vaccines Sales, by Age Group K Liters (2018-2023)
  • Table 194. Mexico HPV Vaccines Sales, by Disease Indication K Liters (2018-2023)
  • Table 195. HPV Vaccines: by Type(USD/Units)
  • Table 196. Company Basic Information, Sales Area and Its Competitors
  • Table 197. Company Basic Information, Sales Area and Its Competitors
  • Table 198. Company Basic Information, Sales Area and Its Competitors
  • Table 199. Company Basic Information, Sales Area and Its Competitors
  • Table 200. Company Basic Information, Sales Area and Its Competitors
  • Table 201. Company Basic Information, Sales Area and Its Competitors
  • Table 202. Company Basic Information, Sales Area and Its Competitors
  • Table 203. Company Basic Information, Sales Area and Its Competitors
  • Table 204. Company Basic Information, Sales Area and Its Competitors
  • Table 205. Company Basic Information, Sales Area and Its Competitors
  • Table 206. HPV Vaccines: by Type(USD Million)
  • Table 207. HPV Vaccines Gardasils , by Region USD Million (2024-2029)
  • Table 208. HPV Vaccines Gardasil 9 , by Region USD Million (2024-2029)
  • Table 209. HPV Vaccines Cervarix , by Region USD Million (2024-2029)
  • Table 210. HPV Vaccines: by Age Group(USD Million)
  • Table 211. HPV Vaccines Adolescent , by Region USD Million (2024-2029)
  • Table 212. HPV Vaccines Adults , by Region USD Million (2024-2029)
  • Table 213. HPV Vaccines: by Disease Indication(USD Million)
  • Table 214. HPV Vaccines Cervical Cancer , by Region USD Million (2024-2029)
  • Table 215. HPV Vaccines Cancer , by Region USD Million (2024-2029)
  • Table 216. HPV Vaccines Vaginal Cancer , by Region USD Million (2024-2029)
  • Table 217. HPV Vaccines Vulvar Cancer , by Region USD Million (2024-2029)
  • Table 218. HPV Vaccines Oropharyngeal Cancer , by Region USD Million (2024-2029)
  • Table 219. HPV Vaccines Others , by Region USD Million (2024-2029)
  • Table 220. South America HPV Vaccines, by Country USD Million (2024-2029)
  • Table 221. South America HPV Vaccines, by Type USD Million (2024-2029)
  • Table 222. South America HPV Vaccines, by Age Group USD Million (2024-2029)
  • Table 223. South America HPV Vaccines, by Disease Indication USD Million (2024-2029)
  • Table 224. Brazil HPV Vaccines, by Type USD Million (2024-2029)
  • Table 225. Brazil HPV Vaccines, by Age Group USD Million (2024-2029)
  • Table 226. Brazil HPV Vaccines, by Disease Indication USD Million (2024-2029)
  • Table 227. Argentina HPV Vaccines, by Type USD Million (2024-2029)
  • Table 228. Argentina HPV Vaccines, by Age Group USD Million (2024-2029)
  • Table 229. Argentina HPV Vaccines, by Disease Indication USD Million (2024-2029)
  • Table 230. Rest of South America HPV Vaccines, by Type USD Million (2024-2029)
  • Table 231. Rest of South America HPV Vaccines, by Age Group USD Million (2024-2029)
  • Table 232. Rest of South America HPV Vaccines, by Disease Indication USD Million (2024-2029)
  • Table 233. Asia Pacific HPV Vaccines, by Country USD Million (2024-2029)
  • Table 234. Asia Pacific HPV Vaccines, by Type USD Million (2024-2029)
  • Table 235. Asia Pacific HPV Vaccines, by Age Group USD Million (2024-2029)
  • Table 236. Asia Pacific HPV Vaccines, by Disease Indication USD Million (2024-2029)
  • Table 237. China HPV Vaccines, by Type USD Million (2024-2029)
  • Table 238. China HPV Vaccines, by Age Group USD Million (2024-2029)
  • Table 239. China HPV Vaccines, by Disease Indication USD Million (2024-2029)
  • Table 240. Japan HPV Vaccines, by Type USD Million (2024-2029)
  • Table 241. Japan HPV Vaccines, by Age Group USD Million (2024-2029)
  • Table 242. Japan HPV Vaccines, by Disease Indication USD Million (2024-2029)
  • Table 243. India HPV Vaccines, by Type USD Million (2024-2029)
  • Table 244. India HPV Vaccines, by Age Group USD Million (2024-2029)
  • Table 245. India HPV Vaccines, by Disease Indication USD Million (2024-2029)
  • Table 246. South Korea HPV Vaccines, by Type USD Million (2024-2029)
  • Table 247. South Korea HPV Vaccines, by Age Group USD Million (2024-2029)
  • Table 248. South Korea HPV Vaccines, by Disease Indication USD Million (2024-2029)
  • Table 249. Taiwan HPV Vaccines, by Type USD Million (2024-2029)
  • Table 250. Taiwan HPV Vaccines, by Age Group USD Million (2024-2029)
  • Table 251. Taiwan HPV Vaccines, by Disease Indication USD Million (2024-2029)
  • Table 252. Australia HPV Vaccines, by Type USD Million (2024-2029)
  • Table 253. Australia HPV Vaccines, by Age Group USD Million (2024-2029)
  • Table 254. Australia HPV Vaccines, by Disease Indication USD Million (2024-2029)
  • Table 255. Rest of Asia-Pacific HPV Vaccines, by Type USD Million (2024-2029)
  • Table 256. Rest of Asia-Pacific HPV Vaccines, by Age Group USD Million (2024-2029)
  • Table 257. Rest of Asia-Pacific HPV Vaccines, by Disease Indication USD Million (2024-2029)
  • Table 258. Europe HPV Vaccines, by Country USD Million (2024-2029)
  • Table 259. Europe HPV Vaccines, by Type USD Million (2024-2029)
  • Table 260. Europe HPV Vaccines, by Age Group USD Million (2024-2029)
  • Table 261. Europe HPV Vaccines, by Disease Indication USD Million (2024-2029)
  • Table 262. Germany HPV Vaccines, by Type USD Million (2024-2029)
  • Table 263. Germany HPV Vaccines, by Age Group USD Million (2024-2029)
  • Table 264. Germany HPV Vaccines, by Disease Indication USD Million (2024-2029)
  • Table 265. France HPV Vaccines, by Type USD Million (2024-2029)
  • Table 266. France HPV Vaccines, by Age Group USD Million (2024-2029)
  • Table 267. France HPV Vaccines, by Disease Indication USD Million (2024-2029)
  • Table 268. Italy HPV Vaccines, by Type USD Million (2024-2029)
  • Table 269. Italy HPV Vaccines, by Age Group USD Million (2024-2029)
  • Table 270. Italy HPV Vaccines, by Disease Indication USD Million (2024-2029)
  • Table 271. United Kingdom HPV Vaccines, by Type USD Million (2024-2029)
  • Table 272. United Kingdom HPV Vaccines, by Age Group USD Million (2024-2029)
  • Table 273. United Kingdom HPV Vaccines, by Disease Indication USD Million (2024-2029)
  • Table 274. Netherlands HPV Vaccines, by Type USD Million (2024-2029)
  • Table 275. Netherlands HPV Vaccines, by Age Group USD Million (2024-2029)
  • Table 276. Netherlands HPV Vaccines, by Disease Indication USD Million (2024-2029)
  • Table 277. Rest of Europe HPV Vaccines, by Type USD Million (2024-2029)
  • Table 278. Rest of Europe HPV Vaccines, by Age Group USD Million (2024-2029)
  • Table 279. Rest of Europe HPV Vaccines, by Disease Indication USD Million (2024-2029)
  • Table 280. MEA HPV Vaccines, by Country USD Million (2024-2029)
  • Table 281. MEA HPV Vaccines, by Type USD Million (2024-2029)
  • Table 282. MEA HPV Vaccines, by Age Group USD Million (2024-2029)
  • Table 283. MEA HPV Vaccines, by Disease Indication USD Million (2024-2029)
  • Table 284. Middle East HPV Vaccines, by Type USD Million (2024-2029)
  • Table 285. Middle East HPV Vaccines, by Age Group USD Million (2024-2029)
  • Table 286. Middle East HPV Vaccines, by Disease Indication USD Million (2024-2029)
  • Table 287. Africa HPV Vaccines, by Type USD Million (2024-2029)
  • Table 288. Africa HPV Vaccines, by Age Group USD Million (2024-2029)
  • Table 289. Africa HPV Vaccines, by Disease Indication USD Million (2024-2029)
  • Table 290. North America HPV Vaccines, by Country USD Million (2024-2029)
  • Table 291. North America HPV Vaccines, by Type USD Million (2024-2029)
  • Table 292. North America HPV Vaccines, by Age Group USD Million (2024-2029)
  • Table 293. North America HPV Vaccines, by Disease Indication USD Million (2024-2029)
  • Table 294. United States HPV Vaccines, by Type USD Million (2024-2029)
  • Table 295. United States HPV Vaccines, by Age Group USD Million (2024-2029)
  • Table 296. United States HPV Vaccines, by Disease Indication USD Million (2024-2029)
  • Table 297. Canada HPV Vaccines, by Type USD Million (2024-2029)
  • Table 298. Canada HPV Vaccines, by Age Group USD Million (2024-2029)
  • Table 299. Canada HPV Vaccines, by Disease Indication USD Million (2024-2029)
  • Table 300. Mexico HPV Vaccines, by Type USD Million (2024-2029)
  • Table 301. Mexico HPV Vaccines, by Age Group USD Million (2024-2029)
  • Table 302. Mexico HPV Vaccines, by Disease Indication USD Million (2024-2029)
  • Table 303. HPV Vaccines Sales: by Type(K Liters)
  • Table 304. HPV Vaccines Sales Gardasils , by Region K Liters (2024-2029)
  • Table 305. HPV Vaccines Sales Gardasil 9 , by Region K Liters (2024-2029)
  • Table 306. HPV Vaccines Sales Cervarix , by Region K Liters (2024-2029)
  • Table 307. HPV Vaccines Sales: by Age Group(K Liters)
  • Table 308. HPV Vaccines Sales Adolescent , by Region K Liters (2024-2029)
  • Table 309. HPV Vaccines Sales Adults , by Region K Liters (2024-2029)
  • Table 310. HPV Vaccines Sales: by Disease Indication(K Liters)
  • Table 311. HPV Vaccines Sales Cervical Cancer , by Region K Liters (2024-2029)
  • Table 312. HPV Vaccines Sales Cancer , by Region K Liters (2024-2029)
  • Table 313. HPV Vaccines Sales Vaginal Cancer , by Region K Liters (2024-2029)
  • Table 314. HPV Vaccines Sales Vulvar Cancer , by Region K Liters (2024-2029)
  • Table 315. HPV Vaccines Sales Oropharyngeal Cancer , by Region K Liters (2024-2029)
  • Table 316. HPV Vaccines Sales Others , by Region K Liters (2024-2029)
  • Table 317. South America HPV Vaccines Sales, by Country K Liters (2024-2029)
  • Table 318. South America HPV Vaccines Sales, by Type K Liters (2024-2029)
  • Table 319. South America HPV Vaccines Sales, by Age Group K Liters (2024-2029)
  • Table 320. South America HPV Vaccines Sales, by Disease Indication K Liters (2024-2029)
  • Table 321. Brazil HPV Vaccines Sales, by Type K Liters (2024-2029)
  • Table 322. Brazil HPV Vaccines Sales, by Age Group K Liters (2024-2029)
  • Table 323. Brazil HPV Vaccines Sales, by Disease Indication K Liters (2024-2029)
  • Table 324. Argentina HPV Vaccines Sales, by Type K Liters (2024-2029)
  • Table 325. Argentina HPV Vaccines Sales, by Age Group K Liters (2024-2029)
  • Table 326. Argentina HPV Vaccines Sales, by Disease Indication K Liters (2024-2029)
  • Table 327. Rest of South America HPV Vaccines Sales, by Type K Liters (2024-2029)
  • Table 328. Rest of South America HPV Vaccines Sales, by Age Group K Liters (2024-2029)
  • Table 329. Rest of South America HPV Vaccines Sales, by Disease Indication K Liters (2024-2029)
  • Table 330. Asia Pacific HPV Vaccines Sales, by Country K Liters (2024-2029)
  • Table 331. Asia Pacific HPV Vaccines Sales, by Type K Liters (2024-2029)
  • Table 332. Asia Pacific HPV Vaccines Sales, by Age Group K Liters (2024-2029)
  • Table 333. Asia Pacific HPV Vaccines Sales, by Disease Indication K Liters (2024-2029)
  • Table 334. China HPV Vaccines Sales, by Type K Liters (2024-2029)
  • Table 335. China HPV Vaccines Sales, by Age Group K Liters (2024-2029)
  • Table 336. China HPV Vaccines Sales, by Disease Indication K Liters (2024-2029)
  • Table 337. Japan HPV Vaccines Sales, by Type K Liters (2024-2029)
  • Table 338. Japan HPV Vaccines Sales, by Age Group K Liters (2024-2029)
  • Table 339. Japan HPV Vaccines Sales, by Disease Indication K Liters (2024-2029)
  • Table 340. India HPV Vaccines Sales, by Type K Liters (2024-2029)
  • Table 341. India HPV Vaccines Sales, by Age Group K Liters (2024-2029)
  • Table 342. India HPV Vaccines Sales, by Disease Indication K Liters (2024-2029)
  • Table 343. South Korea HPV Vaccines Sales, by Type K Liters (2024-2029)
  • Table 344. South Korea HPV Vaccines Sales, by Age Group K Liters (2024-2029)
  • Table 345. South Korea HPV Vaccines Sales, by Disease Indication K Liters (2024-2029)
  • Table 346. Taiwan HPV Vaccines Sales, by Type K Liters (2024-2029)
  • Table 347. Taiwan HPV Vaccines Sales, by Age Group K Liters (2024-2029)
  • Table 348. Taiwan HPV Vaccines Sales, by Disease Indication K Liters (2024-2029)
  • Table 349. Australia HPV Vaccines Sales, by Type K Liters (2024-2029)
  • Table 350. Australia HPV Vaccines Sales, by Age Group K Liters (2024-2029)
  • Table 351. Australia HPV Vaccines Sales, by Disease Indication K Liters (2024-2029)
  • Table 352. Rest of Asia-Pacific HPV Vaccines Sales, by Type K Liters (2024-2029)
  • Table 353. Rest of Asia-Pacific HPV Vaccines Sales, by Age Group K Liters (2024-2029)
  • Table 354. Rest of Asia-Pacific HPV Vaccines Sales, by Disease Indication K Liters (2024-2029)
  • Table 355. Europe HPV Vaccines Sales, by Country K Liters (2024-2029)
  • Table 356. Europe HPV Vaccines Sales, by Type K Liters (2024-2029)
  • Table 357. Europe HPV Vaccines Sales, by Age Group K Liters (2024-2029)
  • Table 358. Europe HPV Vaccines Sales, by Disease Indication K Liters (2024-2029)
  • Table 359. Germany HPV Vaccines Sales, by Type K Liters (2024-2029)
  • Table 360. Germany HPV Vaccines Sales, by Age Group K Liters (2024-2029)
  • Table 361. Germany HPV Vaccines Sales, by Disease Indication K Liters (2024-2029)
  • Table 362. France HPV Vaccines Sales, by Type K Liters (2024-2029)
  • Table 363. France HPV Vaccines Sales, by Age Group K Liters (2024-2029)
  • Table 364. France HPV Vaccines Sales, by Disease Indication K Liters (2024-2029)
  • Table 365. Italy HPV Vaccines Sales, by Type K Liters (2024-2029)
  • Table 366. Italy HPV Vaccines Sales, by Age Group K Liters (2024-2029)
  • Table 367. Italy HPV Vaccines Sales, by Disease Indication K Liters (2024-2029)
  • Table 368. United Kingdom HPV Vaccines Sales, by Type K Liters (2024-2029)
  • Table 369. United Kingdom HPV Vaccines Sales, by Age Group K Liters (2024-2029)
  • Table 370. United Kingdom HPV Vaccines Sales, by Disease Indication K Liters (2024-2029)
  • Table 371. Netherlands HPV Vaccines Sales, by Type K Liters (2024-2029)
  • Table 372. Netherlands HPV Vaccines Sales, by Age Group K Liters (2024-2029)
  • Table 373. Netherlands HPV Vaccines Sales, by Disease Indication K Liters (2024-2029)
  • Table 374. Rest of Europe HPV Vaccines Sales, by Type K Liters (2024-2029)
  • Table 375. Rest of Europe HPV Vaccines Sales, by Age Group K Liters (2024-2029)
  • Table 376. Rest of Europe HPV Vaccines Sales, by Disease Indication K Liters (2024-2029)
  • Table 377. MEA HPV Vaccines Sales, by Country K Liters (2024-2029)
  • Table 378. MEA HPV Vaccines Sales, by Type K Liters (2024-2029)
  • Table 379. MEA HPV Vaccines Sales, by Age Group K Liters (2024-2029)
  • Table 380. MEA HPV Vaccines Sales, by Disease Indication K Liters (2024-2029)
  • Table 381. Middle East HPV Vaccines Sales, by Type K Liters (2024-2029)
  • Table 382. Middle East HPV Vaccines Sales, by Age Group K Liters (2024-2029)
  • Table 383. Middle East HPV Vaccines Sales, by Disease Indication K Liters (2024-2029)
  • Table 384. Africa HPV Vaccines Sales, by Type K Liters (2024-2029)
  • Table 385. Africa HPV Vaccines Sales, by Age Group K Liters (2024-2029)
  • Table 386. Africa HPV Vaccines Sales, by Disease Indication K Liters (2024-2029)
  • Table 387. North America HPV Vaccines Sales, by Country K Liters (2024-2029)
  • Table 388. North America HPV Vaccines Sales, by Type K Liters (2024-2029)
  • Table 389. North America HPV Vaccines Sales, by Age Group K Liters (2024-2029)
  • Table 390. North America HPV Vaccines Sales, by Disease Indication K Liters (2024-2029)
  • Table 391. United States HPV Vaccines Sales, by Type K Liters (2024-2029)
  • Table 392. United States HPV Vaccines Sales, by Age Group K Liters (2024-2029)
  • Table 393. United States HPV Vaccines Sales, by Disease Indication K Liters (2024-2029)
  • Table 394. Canada HPV Vaccines Sales, by Type K Liters (2024-2029)
  • Table 395. Canada HPV Vaccines Sales, by Age Group K Liters (2024-2029)
  • Table 396. Canada HPV Vaccines Sales, by Disease Indication K Liters (2024-2029)
  • Table 397. Mexico HPV Vaccines Sales, by Type K Liters (2024-2029)
  • Table 398. Mexico HPV Vaccines Sales, by Age Group K Liters (2024-2029)
  • Table 399. Mexico HPV Vaccines Sales, by Disease Indication K Liters (2024-2029)
  • Table 400. HPV Vaccines: by Type(USD/Units)
  • Table 401. Research Programs/Design for This Report
  • Table 402. Key Data Information from Secondary Sources
  • Table 403. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global HPV Vaccines: by Type USD Million (2018-2023)
  • Figure 5. Global HPV Vaccines: by Age Group USD Million (2018-2023)
  • Figure 6. Global HPV Vaccines: by Disease Indication USD Million (2018-2023)
  • Figure 7. South America HPV Vaccines Share (%), by Country
  • Figure 8. Asia Pacific HPV Vaccines Share (%), by Country
  • Figure 9. Europe HPV Vaccines Share (%), by Country
  • Figure 10. MEA HPV Vaccines Share (%), by Country
  • Figure 11. North America HPV Vaccines Share (%), by Country
  • Figure 12. Global HPV Vaccines: by Type K Liters (2018-2023)
  • Figure 13. Global HPV Vaccines: by Age Group K Liters (2018-2023)
  • Figure 14. Global HPV Vaccines: by Disease Indication K Liters (2018-2023)
  • Figure 15. South America HPV Vaccines Share (%), by Country
  • Figure 16. Asia Pacific HPV Vaccines Share (%), by Country
  • Figure 17. Europe HPV Vaccines Share (%), by Country
  • Figure 18. MEA HPV Vaccines Share (%), by Country
  • Figure 19. North America HPV Vaccines Share (%), by Country
  • Figure 20. Global HPV Vaccines: by Type USD/Units (2018-2023)
  • Figure 21. Global HPV Vaccines share by Players 2023 (%)
  • Figure 22. Global HPV Vaccines share by Players (Top 3) 2023(%)
  • Figure 23. Global HPV Vaccines share by Players (Top 5) 2023(%)
  • Figure 24. BCG Matrix for key Companies
  • Figure 25. Merck & Co., Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 26. Merck & Co., Inc. (United States) Revenue: by Geography 2023
  • Figure 27. GlaxoSmithKline plc. (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 28. GlaxoSmithKline plc. (United Kingdom) Revenue: by Geography 2023
  • Figure 29. Sanofi S.A. (France) Revenue, Net Income and Gross profit
  • Figure 30. Sanofi S.A. (France) Revenue: by Geography 2023
  • Figure 31. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 32. Pfizer Inc. (United States) Revenue: by Geography 2023
  • Figure 33. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 34. Johnson & Johnson (United States) Revenue: by Geography 2023
  • Figure 35. Inovio Pharmaceuticals Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 36. Inovio Pharmaceuticals Inc. (United States) Revenue: by Geography 2023
  • Figure 37. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 38. Bayer AG (Germany) Revenue: by Geography 2023
  • Figure 39. Nuron Biotech Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 40. Nuron Biotech Inc. (United States) Revenue: by Geography 2023
  • Figure 41. EyeGene Inc. (South Korea) Revenue, Net Income and Gross profit
  • Figure 42. EyeGene Inc. (South Korea) Revenue: by Geography 2023
  • Figure 43. MedImmune (United States) Revenue, Net Income and Gross profit
  • Figure 44. MedImmune (United States) Revenue: by Geography 2023
  • Figure 45. Global HPV Vaccines: by Type USD Million (2024-2029)
  • Figure 46. Global HPV Vaccines: by Age Group USD Million (2024-2029)
  • Figure 47. Global HPV Vaccines: by Disease Indication USD Million (2024-2029)
  • Figure 48. South America HPV Vaccines Share (%), by Country
  • Figure 49. Asia Pacific HPV Vaccines Share (%), by Country
  • Figure 50. Europe HPV Vaccines Share (%), by Country
  • Figure 51. MEA HPV Vaccines Share (%), by Country
  • Figure 52. North America HPV Vaccines Share (%), by Country
  • Figure 53. Global HPV Vaccines: by Type K Liters (2024-2029)
  • Figure 54. Global HPV Vaccines: by Age Group K Liters (2024-2029)
  • Figure 55. Global HPV Vaccines: by Disease Indication K Liters (2024-2029)
  • Figure 56. South America HPV Vaccines Share (%), by Country
  • Figure 57. Asia Pacific HPV Vaccines Share (%), by Country
  • Figure 58. Europe HPV Vaccines Share (%), by Country
  • Figure 59. MEA HPV Vaccines Share (%), by Country
  • Figure 60. North America HPV Vaccines Share (%), by Country
  • Figure 61. Global HPV Vaccines: by Type USD/Units (2024-2029)
List of companies from research coverage that are profiled in the study
  • Merck & Co., Inc. (United States)
  • GlaxoSmithKline plc. (United Kingdom)
  • Sanofi S.A. (France)
  • Pfizer Inc. (United States)
  • Johnson & Johnson (United States)
  • Inovio Pharmaceuticals Inc. (United States)
  • Bayer AG (Germany)
  • Nuron Biotech Inc. (United States)
  • EyeGene Inc. (South Korea)
  • MedImmune (United States)
Select User Access Type

Key Highlights of Report


Jan 2024 214 Pages 90 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
?Global HPV Vaccines Quantitative research analysis
?Global HPV Vaccines Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Merck & Co., Inc. (United States), GlaxoSmithKline plc. (United Kingdom), Sanofi S.A. (France), Pfizer Inc. (United States), Johnson & Johnson (United States), Inovio Pharmaceuticals Inc. (United States), Bayer AG (Germany), Nuron Biotech Inc. (United States), EyeGene Inc. (South Korea) and MedImmune (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"" is seen as one of major influencing trends for HPV Vaccines Market during projected period 2023-2029.
The HPV Vaccines market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About ?Global HPV Vaccines Report?

Have a Query? Click Here

Other Related Reports

Arteriovenous Fistula Treatment Comprehensive Study by Type (Drugs, Transcatheter Embolization, Ultrasound-guided Compression, Surgery), Application (Diagnostic Centers, Hospitals, Clinics, Homecare,...
$ 3750
Brucellosis Vaccines Comprehensive Study by Type (DNA Vaccines, Subunit Vaccines, Vector Vaccines, B. Abortus Recombinant Mutants, Others), Application (Cattle, Sheep, Goats, Pigs, Others), Distribut...
$ 3750
Drugs for Vulvovaginal Candidiasis Comprehensive Study by Type (Miconazole, Clotrimazole, Fluconazole, Econazole, Other), Application (Clotrimazole,, Miconazole,, Terconazole,, Tioconazole,), Formula...
$ 3500
Achondroplasia Treatment Comprehensive Study by Type (RBM-007, TA-46, B-701, Others), Application (Hospital, Clinic, Others) Players and Region - Global Market Outlook to 2030
$ 3500
Hemoperfusion Comprehensive Study by Type (Charcoal Hemoperfusion, Certain Resins Hemoperfusion), Application (Drug Intoxication, Hepatic Encephalopathy, Others), Hemoperfusion Devices (DiaKart, Bioc...
$ 3750
Etanercept Comprehensive Study by Type (Enbrel, Benepali), Application (Rheumatoid arthritis, Psoriatic arthritis, Ankylosing spondylitis, Juvenile idiopathic arthritis (JIA), Others), Form Type (Inj...
$ 3650